Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Satish Garg to Diabetes Mellitus, Type 2

This is a "connection" page, showing publications Satish Garg has written about Diabetes Mellitus, Type 2.

 
Connection Strength
  
 
 
9.431
  
  1. Garg SK, Bailey TS, Castorino K, Christiansen MP, Liljenquist DR, Salazar H, Akturk HK, Gao S, Johnson ML, Beck SE. Accuracy of the 15.5-Day G7 iCGM in Adults with Diabetes. Diabetes Technol Ther. 2025 Jun; 27(6):430-438.
    View in: PubMed
    Score: 0.351
  2. Garg SK, Hirsch IB, Repetto E, Snell-Bergeon J, Ulmer B, Perkins C, Bergenstal RM. Impact of continuous glucose monitoring on hospitalizations and glucose control in people with type 2 diabetes: real-world analysis. Diabetes Obes Metab. 2024 Nov; 26(11):5202-5210.
    View in: PubMed
    Score: 0.339
  3. Garg SK, Kaur G, Haider Z, Rodriquez E, Beatson C, Snell-Bergeon J. Efficacy of Semaglutide in Overweight and Obese Patients with Type 1 Diabetes. Diabetes Technol Ther. 2024 Mar; 26(3):184-189.
    View in: PubMed
    Score: 0.327
  4. Carroll J, Heverly J, Phillip M, Battelino T, Garg S. International Consensus of Continuous Glucose Monitor Use in Pharmacological Clinical Trials in Diabetes. Diabetes Technol Ther. 2023 04; 25(4):217-218.
    View in: PubMed
    Score: 0.304
  5. Garg SK, Rodriguez E, Hirsch IB. New Medications for the Treatment of Diabetes. Diabetes Technol Ther. 2023 02; 25(S1):S207-S216.
    View in: PubMed
    Score: 0.303
  6. Garg SK, Rodriguez E, Shah VN, Hirsch IB. New Medications for the Treatment of Diabetes. Diabetes Technol Ther. 2022 03; 24(S1):S190-S208.
    View in: PubMed
    Score: 0.284
  7. Garg SK, Kipnes M, Castorino K, Bailey TS, Akturk HK, Welsh JB, Christiansen MP, Balo AK, Brown SA, Reid JL, Beck SE. Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with Diabetes. Diabetes Technol Ther. 2022 06; 24(6):373-380.
    View in: PubMed
    Score: 0.284
  8. Garg SK, Liljenquist D, Bode B, Christiansen MP, Bailey TS, Brazg RL, Denham DS, Chang AR, Akturk HK, Dehennis A, Tweden KS, Kaufman FR. Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study. Diabetes Technol Ther. 2022 02; 24(2):84-92.
    View in: PubMed
    Score: 0.275
  9. Garg SK, Hirsch IB. New Medications for the Treatment of Diabetes. Diabetes Technol Ther. 2021 06; 23(S2):S185-S197.
    View in: PubMed
    Score: 0.270
  10. Garg SK, Wernicke-Panten K, Wardecki M, Kramer D, Delalande F, Franek E, Sadeharju K, Monchamp T, Miossec P, Mukherjee B, Shah VN. Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial. Diabetes Technol Ther. 2020 07; 22(7):516-526.
    View in: PubMed
    Score: 0.249
  11. Garg SK, Wernicke-Panten K, Wardecki M, Kramer D, Delalande F, Franek E, Sadeharju K, Monchamp T, Mukherjee B, Shah VN. Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1). Diabetes Technol Ther. 2020 02; 22(2):85-95.
    View in: PubMed
    Score: 0.246
  12. Garg K, Brackett S, Hirsch IB, Garg SK. NAFLD/NASH and Diabetes. Diabetes Technol Ther. 2020 Feb; 22(S1):S174-S186.
    View in: PubMed
    Score: 0.246
  13. Garg SK, Hirsch IB. Self-Monitoring of Blood Glucose. Diabetes Technol Ther. 2019 02; 21(S1):S4-S12.
    View in: PubMed
    Score: 0.230
  14. Garg SK, Giordano D. New Medications for the Treatment of Diabetes. Diabetes Technol Ther. 2019 02; 21(S1):S160-S171.
    View in: PubMed
    Score: 0.230
  15. Wadwa RP, Laffel LM, Shah VN, Garg SK. Accuracy of a Factory-Calibrated, Real-Time Continuous Glucose Monitoring System During 10 Days of Use in Youth and Adults with Diabetes. Diabetes Technol Ther. 2018 06; 20(6):395-402.
    View in: PubMed
    Score: 0.220
  16. Garg SK, Rewers AH, Akturk HK. Ever-Increasing Insulin-Requiring Patients Globally. Diabetes Technol Ther. 2018 06; 20(S2):S21-S24.
    View in: PubMed
    Score: 0.219
  17. Shah VN, Laffel LM, Wadwa RP, Garg SK. Performance of a Factory-Calibrated Real-Time Continuous Glucose Monitoring System Utilizing an Automated Sensor Applicator. Diabetes Technol Ther. 2018 06; 20(6):428-433.
    View in: PubMed
    Score: 0.219
  18. Garg SK, Hirsch IB. Self-Monitoring of Blood Glucose. Diabetes Technol Ther. 2018 02; 20(S1):S3-S12.
    View in: PubMed
    Score: 0.214
  19. Garg SK, Rewers AH, Akturk HK. New Medications for the Treatment of Diabetes. Diabetes Technol Ther. 2018 02; 20(S1):S139-S153.
    View in: PubMed
    Score: 0.214
  20. Singh SK, Singh VK, Kumari P, Nakade UP, Garg SK. Trypanosoma evansi induces detrimental immuno-catabolic alterations and condition like type-2 diabetes in buffaloes. Parasitol Int. 2018 Apr; 67(2):140-143.
    View in: PubMed
    Score: 0.211
  21. Ji L, Zhang P, Zhu D, Li X, Ji J, Lu J, Guo X, Jia W, Weng J, Wu Y, Yang W, Zou D, Zhou Z, Pan C, Gao Y, Garg SK. Observational Registry of Basal Insulin Treatment (ORBIT) in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs: Real-life use of basal insulin in China. Diabetes Obes Metab. 2017 06; 19(6):822-830.
    View in: PubMed
    Score: 0.202
  22. Garg SK, Hirsch IB. Self-Monitoring of Blood Glucose. Diabetes Technol Ther. 2017 02; 19(S1):S3-S10.
    View in: PubMed
    Score: 0.200
  23. Garg SK, Giordano D, Gallo T, Shah VN. New Medications for the Treatment of Diabetes. Diabetes Technol Ther. 2017 02; 19(S1):S128-S140.
    View in: PubMed
    Score: 0.200
  24. Ji L, Zhang P, Weng J, Lu J, Guo X, Jia W, Yang W, Zou D, Zhou Z, Pan C, Gao Y, Li X, Zhu D, Li Y, Wu Y, Garg SK. Observational Registry of Basal Insulin Treatment (ORBIT) in Patients with Type 2 Diabetes Uncontrolled by Oral Hypoglycemic Agents in China--Study Design and Baseline Characteristics. Diabetes Technol Ther. 2015 Oct; 17(10):735-44.
    View in: PubMed
    Score: 0.180
  25. Garg SK, Admane K, Freemantle N, Odawara M, Pan CY, Misra A, Jarek-Martynowa IR, Abbas-Raza S, Mirasol RC, Perfetti R. Patient-led versus physician-led titration of insulin glargine in patients with uncontrolled type 2 diabetes: a randomized multinational ATLAS study. Endocr Pract. 2015 Feb; 21(2):143-57.
    View in: PubMed
    Score: 0.174
  26. Garg SK, Aurand LA, Rimler MS, Dailey GE. Diabetes duration and the efficacy and safety of insulin glargine versus comparator treatment in patients with type 2 diabetes mellitus. Endocr Pract. 2014 Feb; 20(2):120-8.
    View in: PubMed
    Score: 0.162
  27. Ahmann A, Szeinbach SL, Gill J, Traylor L, Garg SK. Comparing patient preferences and healthcare provider recommendations with the pen versus vial-and-syringe insulin delivery in patients with type 2 diabetes. Diabetes Technol Ther. 2014 Feb; 16(2):76-83.
    View in: PubMed
    Score: 0.160
  28. Bhide M, Grey JM, Moser EG, Garg SK. A primary care perspective on the use of continuous glucose monitoring in clinical practice. Diabetes Technol Ther. 2013 Jul; 15(7):533-7.
    View in: PubMed
    Score: 0.156
  29. Garg SK. Standardization of self-monitoring of blood glucose and continuous glucose monitoring reporting. Diabetes Technol Ther. 2013 Mar; 15(3):193.
    View in: PubMed
    Score: 0.152
  30. Garg SK. New therapies for diabetes management. Diabetes Technol Ther. 2013 Feb; 15 Suppl 1:S126-35.
    View in: PubMed
    Score: 0.152
  31. Garg SK, DiDomenico D, Switzer S. Ways to reduce cardiovascular disease in diabetes. Diabetes Technol Ther. 2012 Jun; 14 Suppl 1:S1-2.
    View in: PubMed
    Score: 0.145
  32. Moser EG, Morris AA, Garg SK. Emerging diabetes therapies and technologies. Diabetes Res Clin Pract. 2012 Jul; 97(1):16-26.
    View in: PubMed
    Score: 0.142
  33. Garg SK. Rising epidemic of diabetes and hypertension in Asia. Diabetes Technol Ther. 2012 Jan; 14(1):1-2.
    View in: PubMed
    Score: 0.139
  34. Davis SN, Wei W, Garg S. Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting. Endocr Pract. 2011 Nov-Dec; 17(6):845-52.
    View in: PubMed
    Score: 0.139
  35. Garg SK. Impact of insulin delivery devices in diabetes care. Diabetes Technol Ther. 2010 Jun; 12 Suppl 1:S1-3.
    View in: PubMed
    Score: 0.126
  36. Garg SK. The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review. Diabetes Technol Ther. 2010 Jan; 12(1):11-24.
    View in: PubMed
    Score: 0.122
  37. Garg SK, Kelly WC. Insulin delivery via lungs-is it still possible? Diabetes Technol Ther. 2009 Sep; 11 Suppl 2:S1-3.
    View in: PubMed
    Score: 0.120
  38. Garg SK, Smith J, Beatson C, Lopez-Baca B, Voelmle M, Gottlieb PA. Comparison of accuracy and safety of the SEVEN and the Navigator continuous glucose monitoring systems. Diabetes Technol Ther. 2009 Feb; 11(2):65-72.
    View in: PubMed
    Score: 0.115
  39. Garg SK, Naik RG. Long-acting insulin analogs versus human insulins. Diabetes Technol Ther. 2008 Oct; 10(5):331-2.
    View in: PubMed
    Score: 0.112
  40. Garg S, Kelly WC, Garg S. Insulin glargine and glulisine SoloSTAR pens for the treatment of diabetes. Expert Rev Med Devices. 2008 Mar; 5(2):113-23.
    View in: PubMed
    Score: 0.108
  41. Bailey TS, Zisser HC, Garg SK. Reduction in hemoglobin A1C with real-time continuous glucose monitoring: results from a 12-week observational study. Diabetes Technol Ther. 2007 Jun; 9(3):203-10.
    View in: PubMed
    Score: 0.102
  42. Ellis SL, Gemperline KA, Garg SK. Review of phase 2 studies utilizing the AIR particle technology in the delivery of human insulin inhalation powder versus subcutaneous regular or lispro insulin in subjects with type 1 or type 2 diabetes. Diabetes Technol Ther. 2007 Jun; 9 Suppl 1:S48-56.
    View in: PubMed
    Score: 0.102
  43. Ulrich H, Snyder B, Garg SK. Combining insulins for optimal blood glucose control in type I and 2 diabetes: focus on insulin glulisine. Vasc Health Risk Manag. 2007; 3(3):245-54.
    View in: PubMed
    Score: 0.099
  44. Garg S, Zisser H, Schwartz S, Bailey T, Kaplan R, Ellis S, Jovanovic L. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care. 2006 Jan; 29(1):44-50.
    View in: PubMed
    Score: 0.093
  45. Garg SK. New insulin analogues. Diabetes Technol Ther. 2005 Oct; 7(5):813-7.
    View in: PubMed
    Score: 0.091
  46. Garg SK, Ellis SL, Ulrich H. Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes. Expert Opin Pharmacother. 2005 Apr; 6(4):643-51.
    View in: PubMed
    Score: 0.088
  47. Weinstock RS, Bode BW, Garg SK, Klonoff DC, El Sanadi C, Geho WB, Muchmore DB, Penn MS. Reduced hypoglycaemia using liver-targeted insulin in individuals with type 1 diabetes. Diabetes Obes Metab. 2022 09; 24(9):1762-1769.
    View in: PubMed
    Score: 0.072
  48. Gao L, Zhang P, Weng J, Lu J, Guo X, Jia W, Yang W, Zou D, Zhou Z, Pan C, Gao Y, Li X, Zhu D, Wu Y, Garg SK, Ji L. Patient characteristics and 6-month dose of basal insulin associated with HbA1c achievement <7.0% in Chinese people with type 2 diabetes: results from the Observational Registry of Basal Insulin Treatment (ORBIT). J Diabetes. 2020 Sep; 12(9):668-676.
    View in: PubMed
    Score: 0.063
  49. DeSouza C, Cariou B, Garg S, Lausvig N, Navarria A, Fonseca V. Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials. J Clin Endocrinol Metab. 2020 02 01; 105(2).
    View in: PubMed
    Score: 0.062
  50. Danne T, Garg S, Peters AL, Buse JB, Mathieu C, Pettus JH, Alexander CM, Battelino T, Ampudia-Blasco FJ, Bode BW, Cariou B, Close KL, Dandona P, Dutta S, Ferrannini E, Fourlanos S, Grunberger G, Heller SR, Henry RR, Kurian MJ, Kushner JA, Oron T, Parkin CG, Pieber TR, Rodbard HW, Schatz D, Skyler JS, Tamborlane WV, Yokote K, Phillip M. International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors. Diabetes Care. 2019 06; 42(6):1147-1154.
    View in: PubMed
    Score: 0.057
  51. Akturk HK, Rewers A, Garg SK. SGLT inhibition: a possible adjunctive treatment for type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2018 08; 25(4):246-250.
    View in: PubMed
    Score: 0.055
  52. Garg SK, Polsky S. Continuous glucose monitoring in pregnant women with type 1 diabetes. Lancet. 2017 11 25; 390(10110):2329-2331.
    View in: PubMed
    Score: 0.052
  53. Christiansen MP, Garg SK, Brazg R, Bode BW, Bailey TS, Slover RH, Sullivan A, Huang S, Shin J, Lee SW, Kaufman FR. Accuracy of a Fourth-Generation Subcutaneous Continuous Glucose Sensor. Diabetes Technol Ther. 2017 08; 19(8):446-456.
    View in: PubMed
    Score: 0.052
  54. Ji L, Zhang P, Zhu D, Lu J, Guo X, Wu Y, Li X, Ji J, Jia W, Yang W, Zou D, Zhou Z, Gao Y, Garg SK, Pan C, Weng J, Paul SK. Comparative effectiveness and safety of different basal insulins in a real-world setting. Diabetes Obes Metab. 2017 08; 19(8):1116-1126.
    View in: PubMed
    Score: 0.051
  55. Sussman M, Sierra JA, Garg S, Bode B, Friedman M, Gill M, Kaufman F, Vigersky R, Menzin J. Economic impact of hypoglycemia among insulin-treated patients with diabetes. J Med Econ. 2016 Nov; 19(11):1099-1106.
    View in: PubMed
    Score: 0.048
  56. Fonseca VA, Grunberger G, Anhalt H, Bailey TS, Blevins T, Garg SK, Handelsman Y, Hirsch IB, Orzeck EA, Roberts VL, Tamborlane W. CONTINUOUS GLUCOSE MONITORING: A CONSENSUS CONFERENCE OF THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY. Endocr Pract. 2016 Aug; 22(8):1008-21.
    View in: PubMed
    Score: 0.048
  57. Bailey TS, Ahmann A, Brazg R, Christiansen M, Garg S, Watkins E, Welsh JB, Lee SW. Accuracy and acceptability of the 6-day Enlite continuous subcutaneous glucose sensor. Diabetes Technol Ther. 2014 May; 16(5):277-83.
    View in: PubMed
    Score: 0.041
  58. Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, Garg S, Heinemann L, Hirsch I, Amiel SA, Beck R, Bosi E, Buckingham B, Cobelli C, Dassau E, Doyle FJ, Heller S, Hovorka R, Jia W, Jones T, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Maahs D, Murphy HR, N?rgaard K, Parkin CG, Renard E, Saboo B, Scharf M, Tamborlane WV, Weinzimer SA, Phillip M. International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017 12; 40(12):1631-1640.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)